MediWound (NASDAQ:MDWD) Issues Earnings Results, Beats Expectations By $0.06 EPS

MediWound (NASDAQ:MDWD) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.06, FiscalAI reports. The business had revenue of $3.57 million for the quarter, compared to the consensus estimate of $6.73 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%.

Here are the key takeaways from MediWound’s conference call:

• EscharEx’s VALUE trial remains on track to complete enrollment by the end of Q1 2027, with the interim sample-size reassessment planned for that period; management expects top-line results around mid-2027 if the current study design is unchanged. The latest safety review found no concerns or need for modifications.
• NexoBrid demand and U.S. commercial activity strengthened: Vericel reported its highest quarterly revenue since launch, more than 80 centers have ordered and about 70 have reordered, and BARDA procurement began in Q3. Management said supply constraints, rather than demand, are limiting product sales.
• Global NexoBrid demand currently exceeds manufacturing capacity, and the expanded facility’s commercial supply remains subject to regulatory approval, with a target of the second half of 2027. The company is prioritizing U.S. commercial and government orders while supply remains constrained.
• Q3 revenue fell to $3.6 million from $5.4 million a year earlier, while operating loss widened to $8.5 million from $6.5 million, partly as R&D spending rose to support the VALUE trial. MediWound reported $28.4 million in cash, equivalents and deposits at quarter-end and subsequently raised $17.25 million in a public offering.
• MediWound said a substantial portion of anticipated 2026 revenue depends on funding for a planned U.S.-based manufacturing facility, but it does not know when or whether that funding will be secured. The company said this uncertainty affects its revenue outlook.

MediWound Stock Performance

NASDAQ MDWD traded up $0.26 during trading hours on Friday, hitting $13.23. The company had a trading volume of 28,847 shares, compared to its average volume of 98,533. MediWound has a 52 week low of $11.80 and a 52 week high of $19.70. The firm has a 50 day simple moving average of $13.21 and a 200 day simple moving average of $15.08. The firm has a market capitalization of $172.12 million, a price-to-earnings ratio of -7.35 and a beta of 0.07.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. TD Cowen reissued a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. Weiss Ratings downgraded shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Finally, Oppenheimer reissued an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Insider Buying and Selling at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is currently owned by corporate insiders.

MediWound News Roundup

Investors following MDWD have been watching these news items:

• Positive Sentiment: MediWound said its Phase III VALUE trial of EscharEx is advancing, with an interim assessment and enrollment completion expected by the end of Q1 2027. An article also highlighted potential for the company’s burn treatment to reach a larger market, offering longer-term growth potential. MediWound Q3 results and corporate update MediWound burn drug article
• Neutral Sentiment: Q3 adjusted loss was $0.65 per share, modestly better than the $0.66 Zacks estimate and the $0.71 analyst consensus cited elsewhere. However, the loss widened from $0.24 per share a year earlier. Zacks Q3 earnings report
• Negative Sentiment: Revenue was $3.57 million, about 47% below the $6.73 million analyst expectation. Reports linked the weakness to a stall in U.S. government work. MediWound also withdrew its full-year guidance, increasing uncertainty about near-term revenue and growth. Q3 revenue miss and U.S. government work Full-year guidance withdrawal

About MediWound

MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.